



News Release

Bayer HealthCare Announces Baycox® 5% (toltrazuril) Oral Suspension Approved for Sheep in Canada

TORONTO, ON January 10, 2014 – Bayer HealthCare is pleased to announce Baycox® 5% is now approved to prevent clinical signs of coccidiosis and to reduce coccidian shedding in lambs caused by *Eimeria crandallis* and *Eimeria ovinoidalis*. Canadian veterinarians and producers can now use Baycox 5% to protect lambs from the infection and avoid serious economic losses. In 2010, Health Canada approved Baycox 5% for the treatment of preclinical coccidiosis due to *Isospora suis* in neonatal piglets.

Baycox 5% is a single-dose, ready-to-use product that is easy to administer. A single oral treatment of Baycox controls coccidia infection without impairing the ability of animals to acquire immunity, and promotes resistance to reinfection.ⁱ

Coccidiosis is a disease of the intestinal tract of sheep caused by the protozoa parasites *Eimeria* spp. It is an insidious disease that only becomes evident in infected animals after they show signs such as diarrhea, debilitation, or refusal to feed. Coccidiosis can cause poor growth, loss of appetite and even death in lambs if left untreated.

“A coccidiosis outbreak can put an entire flock at risk. Early preventive treatment is critical for the health of the lambs and, in turn, the financial stability of the producer,” said Matthew Frost, Head, Animal Health, Bayer Inc. “We are excited that Canadian sheep producers are now able to access this product from their veterinarian to help them raise healthier lambs that properly mature, avoiding costly outcomes.”

Coccidiosis is present in almost all sheep rearing countriesⁱⁱ. It is assumed that most, if not all, sheep become infected with coccidia during their livesⁱⁱⁱ, but only some lambs will actually develop clinical symptoms of the disease.

Visible signs of clinical coccidiosis include:

- Diarrhea (with or without mucus or blood)
- Fever
- Loss of appetite
- Abdominal pain
- Weight loss
- Anemia

- Fleece damage

If left untreated, these animals may continue to scour and eventually die of dehydration.^{iv}

Even with its widespread prevalence, the disease can be successfully controlled. Establishing programs that combine management strategies, farm hygiene measures and strategic administration of an anticoccidial like Baycox 5%, can significantly reduce or eliminate clinical coccidiosis in sheep.^v

The arrival of Baycox 5% to the Canadian market has been made possible through a cooperative effort between Bayer HealthCare and the Veterinary Drugs Directorate, a part of the Health Products and Food Branch of Health Canada. Baycox 5% was approved for use in Canada through an initiative to provide a streamlined and simplified approval process for licensing drugs for minor use and minor species.

-30-

About Baycox® 5%

Baycox 5% is an oral medication indicated for the treatment of preclinical coccidiosis due to *Isospora suis* in neonatal piglets, and for the prevention of clinical signs of coccidiosis and the reduction of coccidian shedding in lambs caused by *Eimeria crandallis* and *Eimeria ovinoidalis*.

About Bayer in Canada

Bayer Inc. is a Canadian subsidiary of Bayer AG and the corporate headquarters for the Canadian operations. Founded in 1863, Bayer AG is an international research-based group with core businesses in healthcare, crop science and innovative materials committed to creating a better life for all through science.

In Canada, Bayer operates its healthcare business – Pharmaceuticals, Consumer Care, Diabetes Care, Animal Health and Radiology & Interventional – from its headquarters in Toronto, ON, and Bayer CropScience Inc. operates out of its head office in Calgary, AB. Together with its material science business, Bayer improves the quality of life for Canadians through products that fight disease, protect crops and animals, and provide high-performance materials for numerous daily life uses.

With more than 1,300 employees across the country, in 2012, Bayer had sales of \$1.6 billion and invested \$55.9 million in research and development in Canada. Globally, Bayer AG had sales of €39.8 billion and invested €3 billion in research and development.

For more information about Bayer, please visit www.bayer.ca.

For more information, contact:

Emily Hanft, 416.24.5466

emily.hanft@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

ⁱ (Steinfelder, et al., 2005)

ⁱⁱ (Pellerdy, 1974)

ⁱⁱⁱ (Taylor and Catchpole, 1994)

^{iv} (Taylor, 1995)

^v (Foreyt, 1986)